Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Depreciation & Amortization (CF): 2012-2024

Historic Depreciation & Amortization (CF) for Ocular Therapeutix (OCUL) over the last 13 years, with Dec 2024 value amounting to $3.8 million.

  • Ocular Therapeutix's Depreciation & Amortization (CF) rose 11.47% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.0 million, marking a year-over-year increase of 6.17%. This contributed to the annual value of $3.8 million for FY2024, which is 26.92% up from last year.
  • As of FY2024, Ocular Therapeutix's Depreciation & Amortization (CF) stood at $3.8 million, which was up 26.92% from $3.0 million recorded in FY2023.
  • Ocular Therapeutix's Depreciation & Amortization (CF)'s 5-year high stood at $3.8 million during FY2024, with a 5-year trough of $2.1 million in FY2022.
  • Moreover, its 3-year median value for Depreciation & Amortization (CF) was $3.0 million (2023), whereas its average is $3.0 million.
  • As far as peak fluctuations go, Ocular Therapeutix's Depreciation & Amortization (CF) fell by 12.89% in 2022, and later spiked by 41.44% in 2023.
  • Ocular Therapeutix's Depreciation & Amortization (CF) (Yearly) stood at $2.8 million in 2020, then dropped by 12.69% to $2.4 million in 2021, then dropped by 12.89% to $2.1 million in 2022, then spiked by 41.44% to $3.0 million in 2023, then increased by 26.92% to $3.8 million in 2024.